Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy KemPharm stock

Learn how to easily invest in KemPharm stock.

KemPharm is currently traded as an over-the-counter (OTC) stock, which means that some shares are available, but not easy to access. The company plans to list on the Nasdaq, which will make it easy to buy shares from any major brokerage account. Here's how.

How to buy shares in KemPharm

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KMPH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

KemPharm stock price (NASDAQ: KMPH)

Use our graph to track the performance of KMPH stocks over time.

KemPharm shares at a glance

Information last updated 2022-07-01.
Latest market close$4.50
52-week range$4.00 - $13.55
50-day moving average $4.52
200-day moving average $6.79
Wall St. target price$19.50
PE ratio 13.1176
Dividend yield $0 (0%)
Earnings per share (TTM) $0.34

Buy KemPharm shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
Stocks, ETFs, Cryptocurrency
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Axos Bank Self Directed Investing
when you open an account and deposit at least $1500.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy KemPharm stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

KemPharm price performance over time

Historical closes compared with the close of $4.5 from 2022-07-01

1 week (2022-06-28) -0.44%
1 month (2022-06-01) N/A
3 months (2022-04-04) -13.63%
6 months (2022-01-01) N/A
1 year (2021-07-02) -65.25%
2 years (2020-07-02) 1,452.80%
3 years (2019-07-05) 181.25%
5 years (2017-07-05) 25.00%

Is KemPharm stock undervalued or overvalued?

Valuing KemPharm stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of KemPharm's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

KemPharm's P/E ratio

KemPharm's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, KemPharm shares trade at around 13x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, KemPharm's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

KemPharm financials

Revenue TTM $20.5 million
Gross profit TTM $26.6 million
Return on assets TTM -0.63%
Return on equity TTM -0.12%
Profit margin -0.6%
Book value $3.53
Market capitalisation $153.5 million

TTM: trailing 12 months

KemPharm share dividends

We're not expecting KemPharm to pay a dividend over the next 12 months.

You may also wish to consider:

Have KemPharm's shares ever split?

KemPharm's shares were split on a 1:16 basis on 27 December 2020. So if you had owned 16 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your KemPharm shares – just the quantity. However, indirectly, the new 1500% higher share price could have impacted the market appetite for KemPharm shares which in turn could have impacted KemPharm's share price.

KemPharm share price volatility

Over the last 12 months, KemPharm's shares have ranged in value from as little as $4 up to $13.55. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while KemPharm's is 2.9555. This would suggest that KemPharm's shares are significantly more volatile than the average for this exchange and represent a higher risk.

To put KemPharm's beta into context you can compare it against those of similar companies.

KemPharm overview

KemPharm, Inc. , a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.

Frequently asked questions

What percentage of KemPharm is owned by insiders or institutions?
Currently 12.28% of KemPharm shares are held by insiders and 29.672% by institutions.
How many people work for KemPharm?
Latest data suggests 24 work at KemPharm.
When does the fiscal year end for KemPharm?
KemPharm's fiscal year ends in December.
Where is KemPharm based?
KemPharm's address is: 1180 Celebration Boulevard, Celebration, FL, United States, 34747
What is KemPharm's ISIN number?
KemPharm's international securities identification number is: US4884452065
What is KemPharm's CUSIP number?
KemPharm's Committee on Uniform Securities Identification Procedures number is: 488445107

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site